DECISION : Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial

• Tyrosine Kinase inhibitors are indicated in patients with a significant DTC tumor burden, symptomatic, rapidly progressive and/or imminently threatening disease. (ATA thyroid cancer guidelines 2015)

• Lenvatinib, another TKI was also efficacious in DTC (SELECT study)



Brose, Marcia S et al. “Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.” Lancet (London, England) vol. 384,9940 (2014): 319-28.

About the author 


The MyEndoconsult Team. A group of physicians dedicated to endocrinology and internal medicine education.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Pathophysiology Videos


  • Learn Basic Physiology
  • Pathophysiology (Advanced Concepts)
  • Clinical Correlates